AI Article Synopsis
- The effectiveness of skin tests for diagnosing adverse drug reactions (ADRs) is limited due to a lack of understanding of drug allergens.
- Reports suggest that metabolites, particularly a carbamazepine (CBZ) metabolite, play a significant role in skin reactions.
- In a study, skin tests with CBZ and its metabolite CBZ-epoxide showed positive results in 10 out of 13 patients with CBZ-induced skin reactions, highlighting the importance of testing both drugs and their metabolites for better diagnostic accuracy.
Article Abstract
The value of skin tests in the diagnosis of adverse drug reactions (ADRs) has been limited. Lack of knowledge as to the nature of drug allergens has contributed to these limitations. Several reports have addressed the roles of metabolites in cutaneous ADRs and skin testing. We evaluated the role of a carbamazepine (CBZ) metabolite on the results obtained from patch tests, using CBZ and its main metabolite 10, 11-epoxide of CBZ (CBZ-epoxide), on 13 patients with CBZ-induced drug eruptions and 39 controls with no CBZ-induced cutaneous ADRs. 10 of the 13 patients showed a positive reaction, and 2 of the 10 patients had a reaction to the CBZ-epoxide only and 1 to both CBZ and CBZ-epoxide. None of the 39 controls displayed any reactions to either CBZ or CBZ-epoxide. Patch testing of suspected drugs, as well as their available metabolites, would be helpful in improving the results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1034/j.1600-0536.2003.00065.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!